Retirement Wealth Solutions LLC Invests $327,000 in Exact Sciences Co. (NASDAQ:EXAS)

Retirement Wealth Solutions LLC bought a new stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 5,782 shares of the medical research company's stock, valued at approximately $327,000.

A number of other hedge funds have also made changes to their positions in EXAS. Acadian Asset Management LLC acquired a new position in Exact Sciences in the second quarter worth approximately $160,000. Dimensional Fund Advisors LP increased its stake in shares of Exact Sciences by 12.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,002,784 shares of the medical research company's stock worth $42,389,000 after purchasing an additional 108,296 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its holdings in shares of Exact Sciences by 12.9% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 32,081 shares of the medical research company's stock valued at $1,358,000 after purchasing an additional 3,674 shares in the last quarter. Amalgamated Bank lifted its stake in shares of Exact Sciences by 2.7% in the 2nd quarter. Amalgamated Bank now owns 10,937 shares of the medical research company's stock valued at $462,000 after purchasing an additional 284 shares during the last quarter. Finally, Blair William & Co. IL boosted its holdings in Exact Sciences by 28.8% in the second quarter. Blair William & Co. IL now owns 446,686 shares of the medical research company's stock worth $18,872,000 after purchasing an additional 99,817 shares in the last quarter. 88.82% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Robert W. Baird lowered their target price on shares of Exact Sciences from $70.00 to $67.00 and set an "outperform" rating on the stock in a research note on Wednesday, November 6th. BTIG Research raised their price target on Exact Sciences from $65.00 to $75.00 and gave the company a "buy" rating in a research report on Tuesday, November 26th. William Blair reissued an "outperform" rating on shares of Exact Sciences in a research report on Monday, January 13th. Sanford C. Bernstein raised their target price on Exact Sciences from $75.00 to $90.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th. Finally, Raymond James reaffirmed a "market perform" rating on shares of Exact Sciences in a research report on Thursday, September 26th. One equities research analyst has rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $72.94.

Insider Buying and Selling

In other Exact Sciences news, CEO Kevin T. Conroy bought 19,500 shares of Exact Sciences stock in a transaction that occurred on Wednesday, November 13th. The stock was acquired at an average price of $51.35 per share, for a total transaction of $1,001,325.00. Following the completion of the acquisition, the chief executive officer now owns 1,074,191 shares of the company's stock, valued at $55,159,707.85. This trade represents a 1.85 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.36% of the stock is owned by company insiders.

Exact Sciences Price Performance

NASDAQ EXAS traded up $1.30 on Friday, hitting $51.74. 2,930,977 shares of the company were exchanged, compared to its average volume of 1,384,925. Exact Sciences Co. has a 1-year low of $40.62 and a 1-year high of $79.62. The firm has a 50 day moving average of $57.15 and a two-hundred day moving average of $59.26. The company has a market cap of $9.58 billion, a P/E ratio of -44.22 and a beta of 1.24. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The company had revenue of $708.66 million during the quarter, compared to the consensus estimate of $716.80 million. The business's quarterly revenue was up 12.8% on a year-over-year basis. On average, equities analysts predict that Exact Sciences Co. will post -1.1 EPS for the current year.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.